Retrospective case analysis of childhood Philadelphila chromosome-positive acute lymphoblastic leukemia not enrolled in clinical trials in the tyrosine kinase inhibitor era.

Retrospective case analysis of childhood Philadelphila chromosome-positive acute lymphoblastic leukemia not enrolled in clinical trials in the tyrosine kinase inhibitor era. - JPLSG-Ph+ALL Retro

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029171

Enrollment

Registered

2017-09-19

Start date

2017-09-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Philadelphila chromosome-positive acute lymphoblastic leukemia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Those who fulfill two conditions as follows are eligible; (1) the patient who were excluded from Japan Pediatric Leukemia Lymphoma Study Group (JPLSG) ALL-B12 study because of diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia after entry to JPLSG ALL-B12 study; (2) the patient who were not enrolled in Japan Pediatric Leukemia Lymphoma Study Group (JPLSG) ALL-Ph13 study.

Exclusion criteria

Exclusion criteria: Those who were considered inappropriate for entry to the current investigation by attending physician.

Design outcomes

Primary

Measure	Time frame
Induction rate defined by chemotherapeutics	—

Countries

Japan

Contacts

Public ContactKeisuke Kato, M.D.

Ibaraki Children's Hospital Division of Pediatric Hematology and Oncology, Specialty Care Service, Pediatrics

keikato-ind@umin.ac.jp029-254-1151

Outcome results